Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004162 · ClinicalTrials.gov registry record · Phase 1
Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00004162 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 48 participants.
The verdict
NCT00004162, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin plus combination chemotherapy in treating patients who have AIDS-associated non-Hodgkin's lymphoma.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
- DRUG methotrexate
- BIOLOGICAL sargramostim
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 1997-06 |
| Est. Completion | 2001-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004162
The ClinicalTrials.gov registry entry for NCT00004162 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00004162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004162 about?
NCT00004162 is a clinical study titled "Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin plus combination chemotherapy in treating pati...
What is the current status of trial NCT00004162?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 1997-06. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00004162?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), methotrexate (DRUG), sargramostim (BIOLOGICAL), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00004162?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.